

ASX Release

20 September 2016

LifeHealthcare Group Limited Presents at Finance News Network CEO Series

LifeHealthcare Group Limited (ASX: LHC) is presenting at the Finance News Network CEO Series today, a copy of the presentation is attached.

For further information contact:

Kristine James General Manager Corporate Development +61 2 8114 1534 kristine.james@lifehealthcare.com.au

> Not your typical multinational

LifeHealthcare > Not your typical multinational

Finance News Network CEO Sessions

20 September 2016

Matt Muscio Chief Executive Officer



>Market Orientation



Competitive advantage generated through a high degree of market orientation and a compelling value proposition




Value Proposition

- Scale of a multinational without being constrained by a single foreign parent company
- Rapid access to innovation
- Global reach, local tailored solutions, best in class products
- Local ownership ensures decision makers are readily accessible
- Focused on the needs of only Australian and New Zealand customers
- > We act with speed and conviction

> Full Service Integrated Business Model




A full service offering and tailored solutions for customers within the Australian and New Zealand healthcare market



>Broad Therapeutic Offering



Established presence in 7 therapeutic channels providing implants, capital and consumables. Further entry into plastics and wound management channels with Biologics offering currently undergoing TGA approval



Spine

Orthopaedics

Cardiology

General Surgery

Neurophysiology

Ultrasound

Theatre Capital

Surgical Instruments & Consumables

Supported by regulatory and compliance, dedicated service teams and operations

Neurosurgery



Marketing, **Regulatory Affairs** & Product Management



Endovascular

& Respiratory

Customer Service



Kit & Consignment



Inventory &

Logistics




Warehouse & Distribution


Consistent Track Record of Growth




Delivering consistent growth in the number of active surgeons, revenue and earnings

Active Surgeons¹





EBITDA²



Notes:

1. Active surgeons are surgeons who generate \$50,000 or more of revenue in that period (excluding biologics) for LifeHealthcare

2. Underlying EBITDA excludes acquisition transaction costs in FY15 and FY16

Revenue per active surgeon (\$'000)

4

> FY16 Results Key Metrics



A solid performance for FY16 with 15.6% revenue growth on prior year



- Notes:
- 1. Underlying EBITDA excludes acquisition transaction costs
- 2. Final dividend of 7.5 cents 100% unfranked

> LifeHealthcare Strategic Priorities



Strategic priorities aligned with LifeHealthcare's vision of connecting Australian and New Zealand healthcare professionals with innovative and tailored health solutions to make a real difference to people's lives

Organisational Efficiency & Effectiveness



Driving automation and improvements to systems and processes to support the business Channel Optimisation



Increasing market share and providing greater breadth of offering in therapeutic divisions Three phased approach to expand into emerging Biologics technology

Biologics

Growth

Develop Solutions to Address Changing Needs of Healthcare



Addressing healthcare needs including healthcare economics, connectivity, pre and post operative care etc.

Delivering strong sustainable shareholder value over time

> Outlook



Positioned to deliver sustained above market growth

- Solid above market revenue growth expected to be maintained through expansion of active surgeons across implant channels and continued leverage of acquisitions
- Channel investment poised to drive future growth with PHI related price adjustments anticipated from FY18 onwards
- Price increases and improved supplier purchasing terms partially offset gross margin impact from sustained foreign exchange rate deterioration and mix
- Investment in systems and processes to deliver increased efficiencies providing leverage on operating expenses and enhancing business model robustness
- Prudent balance sheet management with improved working capital ratios, positive cash conversion and debt repayment
- Consistent approach to dividend distribution with 50-70% payout of NPATA

MID TO HIGH SINGLE DIGIT REVENUE GROWTH

FY17 revenue growth expected to be in the mid to high single digits representing a sustained above market performance

Low to mid single digit EBITDA growth. EBITDA impacted by weaker USD/AUD, outlook assumes average rate in FY17 of 73 cents

Disclaimer



The material in this presentation has been prepared by LifeHealthcare Group Limited ABN 72 166 525 186 ("LifeHealthcare") to provide shareholders with information on the business.

Information in this presentation should not be considered as advice or a recommendation to investors or potential investors and does not take into account investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice when deciding if an investment is appropriate. Persons needing advice should consult their stockbroker, solicitor, accountant or other independent financial advisor.

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law.

Thank you



Subscribe to company news at www.lifehealthcare.com.au/investors/